Po‐Lin Tseng

1.5k total citations
57 papers, 1.2k citations indexed

About

Po‐Lin Tseng is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Po‐Lin Tseng has authored 57 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hepatology, 49 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Po‐Lin Tseng's work include Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (41 papers) and Hepatitis B Virus Studies (35 papers). Po‐Lin Tseng is often cited by papers focused on Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (41 papers) and Hepatitis B Virus Studies (35 papers). Po‐Lin Tseng collaborates with scholars based in Taiwan, United States and Slovenia. Po‐Lin Tseng's co-authors include Tsung‐Hui Hu, Kuo‐Chin Chang, Sheng‐Nan Lu, Yi‐Hao Yen, Chien‐Hung Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Kwong‐Ming Kee, Ming‐Tsung Lin and Chao‐Hung Hung and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Hepatology.

In The Last Decade

Po‐Lin Tseng

57 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Po‐Lin Tseng Taiwan	22	884	869	174	136	93	57	1.2k
Takanori Hosokawa Japan	21	841 1.0×	921 1.1×	158 0.9×	93 0.7×	115 1.2×	33	1.2k
Yasuhiro Hisanaga Japan	20	918 1.0×	1.0k 1.2×	133 0.8×	146 1.1×	142 1.5×	58	1.3k
Melisa Dirchwolf Argentina	14	512 0.6×	543 0.6×	221 1.3×	169 1.2×	117 1.3×	27	987
Gi‐Ae Kim South Korea	16	1.3k 1.4×	1.1k 1.3×	117 0.7×	134 1.0×	87 0.9×	43	1.5k
Kai‐Henrik Peiffer Germany	14	463 0.5×	468 0.5×	133 0.8×	92 0.7×	62 0.7×	47	734
Goki Suda Japan	19	433 0.5×	475 0.5×	332 1.9×	162 1.2×	140 1.5×	71	1.0k
Ning‐Ping Zhang China	13	495 0.6×	337 0.4×	215 1.2×	87 0.6×	87 0.9×	28	768
Nirupama Trehanpati India	15	618 0.7×	635 0.7×	214 1.2×	123 0.9×	93 1.0×	27	1.1k
Chan Ran You South Korea	14	426 0.5×	516 0.6×	70 0.4×	113 0.8×	162 1.7×	30	776
Pietro Casarin Italy	14	769 0.9×	637 0.7×	317 1.8×	127 0.9×	144 1.5×	22	1.1k

Countries citing papers authored by Po‐Lin Tseng

Since Specialization

Citations

This map shows the geographic impact of Po‐Lin Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po‐Lin Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po‐Lin Tseng more than expected).

Fields of papers citing papers by Po‐Lin Tseng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po‐Lin Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po‐Lin Tseng. The network helps show where Po‐Lin Tseng may publish in the future.

Co-authorship network of co-authors of Po‐Lin Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Po‐Lin Tseng. A scholar is included among the top collaborators of Po‐Lin Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po‐Lin Tseng. Po‐Lin Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Tsung‐Hui, Yeh‐Pin Chou, Yuan‐Hung Kuo, et al.. (2023). Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. Journal of Infection and Public Health. 16(11). 1852–1859. 1 indexed citations

Hu, Tsung‐Hui, Sherry Yueh‐Hsia Chiu, Po‐Lin Tseng, et al.. (2020). Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan. Alimentary Pharmacology & Therapeutics. 52(11-12). 1695–1706. 14 indexed citations

Tseng, Po‐Lin, Tsung‐Hui Hu, Chih‐Wei Chen, et al.. (2018). Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Scientific Reports. 8(1). 3081–3081. 75 indexed citations

Yen, Yi‐Hao, Ming‐Tsung Lin, Fang‐Ying Kuo, et al.. (2017). The association between steatosis and diabetes with hepatocellular carcinoma in non‐genotype 3 chronic hepatitis C patients. Liver International. 38(6). 1064–1073. 14 indexed citations

Hu, Tsung‐Hui, Kuo‐Chin Chang, Po‐Lin Tseng, et al.. (2017). Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy. Medicine. 96(46). e8696–e8696. 9 indexed citations

Yen, Yi‐Hao, Jung‐Fu Chen, Cheng‐Kun Wu, et al.. (2017). The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. Journal of the Formosan Medical Association. 116(11). 852–861. 10 indexed citations

Yen, Yi‐Hao, Kuo‐Chin Chang, Ming‐Chao Tsai, et al.. (2017). Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. Journal of the Formosan Medical Association. 117(4). 268–275. 17 indexed citations

Wu, Cheng‐Kun, Kuo‐Chin Chang, Chao‐Hung Hung, et al.. (2016). Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. Journal of Antimicrobial Chemotherapy. 71(7). 1943–1947. 20 indexed citations

Tsai, Ming‐Chao, Chia‐Hsiang Chen, Po‐Lin Tseng, et al.. (2015). Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clinical Microbiology and Infection. 22(1). 95.e1–95.e7. 50 indexed citations

10.

Chen, Chien‐Hung, Chih‐Lang Lin, Tsung‐Hui Hu, et al.. (2014). Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. Journal of Hepatology. 60(6). 1127–1134. 39 indexed citations

11.

Chang, Kuo‐Chin, Po‐Lin Tseng, Yi‐Ying Wu, et al.. (2014). A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 13(5). 1017–1024. 46 indexed citations

12.

Tseng, Po‐Lin, Jing‐Houng Wang, Chao‐Hung Hung, et al.. (2013). Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. The Kaohsiung Journal of Medical Sciences. 29(7). 385–395. 15 indexed citations

13.

Wu, Y-Y, Chien‐Hui Hung, Chi‐Ming Lee, et al.. (2013). Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. British Journal of Cancer. 109(9). 2481–2488. 49 indexed citations

14.

Hung, Chien‐Hui, J.-H. Wang, C.-M. Lee, et al.. (2012). A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. Journal of Antimicrobial Chemotherapy. 67(11). 2766–2772. 71 indexed citations

15.

Tsai, Ming‐Chao, C.-M. Lee, King‐Wah Chiu, et al.. (2011). A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. Journal of Antimicrobial Chemotherapy. 67(3). 696–699. 25 indexed citations

16.

Tung, Hung‐Da, Jing‐Houng Wang, Po‐Lin Tseng, et al.. (2010). Neither Diabetes Mellitus nor Overweight Is a Risk Factor for Hepatocellular Carcinoma in a Dual HBV and HCV Endemic Area: Community Cross-Sectional and Case–Control Studies. The American Journal of Gastroenterology. 105(3). 624–631. 41 indexed citations

17.

Tseng, Po‐Lin, Jing‐Houng Wang, Hung‐Da Tung, et al.. (2010). Optimal treatment increased survival of hepatocellular carcinoma patients detected with community‐based screening. Journal of Gastroenterology and Hepatology. 25(8). 1426–1434. 32 indexed citations

18.

Chen, Jingyi, Jing‐Houng Wang, Chih‐Yun Lin, et al.. (2010). Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both Hepatitis B and C strains independently. Journal of Gastroenterology and Hepatology. 25(11). 1763–1768. 44 indexed citations

19.

Kuo, Yuan‐Hung, Chien‐Hung Chen, Jing‐Houng Wang, et al.. (2009). Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scandinavian Journal of Gastroenterology. 45(1). 75–81. 31 indexed citations

20.

Tseng, Po‐Lin, et al.. (2005). Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus‐related decompensated liver cirrhosis. Journal of Viral Hepatitis. 12(4). 386–392. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact